286 related articles for article (PubMed ID: 34518645)
1. Clinical and biological aspects of myeloid leukemia in Down syndrome.
Boucher AC; Caldwell KJ; Crispino JD; Flerlage JE
Leukemia; 2021 Dec; 35(12):3352-3360. PubMed ID: 34518645
[TBL] [Abstract][Full Text] [Related]
2. Evolution of myeloid leukemia in children with Down syndrome.
Saida S
Int J Hematol; 2016 Apr; 103(4):365-72. PubMed ID: 26910243
[TBL] [Abstract][Full Text] [Related]
3. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
Garnett C; Cruz Hernandez D; Vyas P
IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
[TBL] [Abstract][Full Text] [Related]
4. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
Kanezaki R; Toki T; Terui K; Xu G; Wang R; Shimada A; Hama A; Kanegane H; Kawakami K; Endo M; Hasegawa D; Kogawa K; Adachi S; Ikeda Y; Iwamoto S; Taga T; Kosaka Y; Kojima S; Hayashi Y; Ito E
Blood; 2010 Nov; 116(22):4631-8. PubMed ID: 20729467
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
Watanabe K
Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
[TBL] [Abstract][Full Text] [Related]
6. GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
Lum SH; Choong SS; Krishnan S; Mohamed Z; Ariffin H
Singapore Med J; 2016 Jun; 57(6):320-4. PubMed ID: 27353457
[TBL] [Abstract][Full Text] [Related]
7. [Myeloid proliferations related to Down syndrome].
Hasegawa D
Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
[TBL] [Abstract][Full Text] [Related]
8. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.
Roy A; Roberts I; Vyas P
Semin Fetal Neonatal Med; 2012 Aug; 17(4):196-201. PubMed ID: 22421527
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for Diagnosis and Treatment of Children with Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome (ML-DS).
Al-Kershi S; Golnik R; Flasinski M; Waack K; Rasche M; Creutzig U; Dworzak M; Reinhardt D; Klusmann JH
Klin Padiatr; 2021 Nov; 233(6):267-277. PubMed ID: 34407551
[TBL] [Abstract][Full Text] [Related]
10. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
Bhatnagar N; Nizery L; Tunstall O; Vyas P; Roberts I
Curr Hematol Malig Rep; 2016 Oct; 11(5):333-41. PubMed ID: 27510823
[TBL] [Abstract][Full Text] [Related]
11. A sensitive and inexpensive high-resolution melting-based testing algorithm for diagnosis of transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.
Camargo R; de Castro Moreira Dos Santos A; Cândido Guido B; Lemos Mendanha Cavalcante L; Silva Dias AC; Mendonça de Pontes R; Magalhães Furtado F; Feitosa Salviano C; Tiziani V; Martins Córdoba JC; Quezado Magalhães IM
Pediatr Blood Cancer; 2022 Nov; 69(11):e29866. PubMed ID: 35731576
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
Labuhn M; Perkins K; Matzk S; Varghese L; Garnett C; Papaemmanuil E; Metzner M; Kennedy A; Amstislavskiy V; Risch T; Bhayadia R; Samulowski D; Hernandez DC; Stoilova B; Iotchkova V; Oppermann U; Scheer C; Yoshida K; Schwarzer A; Taub JW; Crispino JD; Weiss MJ; Hayashi Y; Taga T; Ito E; Ogawa S; Reinhardt D; Yaspo ML; Campbell PJ; Roberts I; Constantinescu SN; Vyas P; Heckl D; Klusmann JH
Cancer Cell; 2019 Aug; 36(2):123-138.e10. PubMed ID: 31303423
[TBL] [Abstract][Full Text] [Related]
13. Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome.
Saida S; Watanabe K; Sato-Otsubo A; Terui K; Yoshida K; Okuno Y; Toki T; Wang R; Shiraishi Y; Miyano S; Kato I; Morishima T; Fujino H; Umeda K; Hiramatsu H; Adachi S; Ito E; Ogawa S; Ito M; Nakahata T; Heike T
Blood; 2013 May; 121(21):4377-87. PubMed ID: 23482930
[TBL] [Abstract][Full Text] [Related]
14. Hematological disorders in children with Down syndrome.
Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
[TBL] [Abstract][Full Text] [Related]
15. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
[TBL] [Abstract][Full Text] [Related]
16. Distinctive hematological abnormalities in East Asian neonates and children with Down syndrome.
Kim DW; Kim HR; Shin MG; Baek HJ; Kook H; Hwang TJ; Shin JH; Suh SP; Ryang DW
Int J Lab Hematol; 2011 Aug; 33(4):369-77. PubMed ID: 21692995
[TBL] [Abstract][Full Text] [Related]
17. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.
Alford KA; Reinhardt K; Garnett C; Norton A; Böhmer K; von Neuhoff C; Kolenova A; Marchi E; Klusmann JH; Roberts I; Hasle H; Reinhardt D; Vyas P;
Blood; 2011 Aug; 118(8):2222-38. PubMed ID: 21715302
[TBL] [Abstract][Full Text] [Related]
18. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
[TBL] [Abstract][Full Text] [Related]
19. PRAME immunohistochemical staining in transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome.
Chisholm KM; Rivetta CV; Heerema-McKenney A
Ann Clin Lab Sci; 2015; 45(2):121-7. PubMed ID: 25887863
[TBL] [Abstract][Full Text] [Related]
20. Haematopoietic development and leukaemia in Down syndrome.
Roberts I; Izraeli S
Br J Haematol; 2014 Dec; 167(5):587-99. PubMed ID: 25155832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
